Pulmatrix Revenue 2014-2022 | PULM
Pulmatrix revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Pulmatrix Annual Revenue
(Millions of US $) |
| 2021 |
$5 |
| 2020 |
$13 |
| 2019 |
$8 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$1 |
| 2015 |
$1 |
| 2014 |
$0 |
| 2014 |
$ |
| 2013 |
$ |
| 2013 |
$ |
| 2012 |
$ |
Pulmatrix Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$2 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$4 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$2 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2017-09-30 |
$0 |
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$0 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
|
| 2014-09-30 |
$0 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.015B |
$0.005B |
|
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|
